WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1999007375) USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING AGGRESSIVE BEHAVIOUR DISORDERS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1999/007375    International Application No.:    PCT/EP1998/004933
Publication Date: 18.02.1999 International Filing Date: 31.07.1998
Chapter 2 Demand Filed:    21.01.1999    
IPC:
A61K 31/439 (2006.01)
Applicants: MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB) (AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BY, CA, CF, CG, CH, CI, CM, CN, CU, CY, CZ, DE, DK, EE, ES, FI, FR, GA, GB, GE, GH, GM, GN, GR, GW, HR, HU, ID, IE, IL, IS, IT, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MC, MD, MG, MK, ML, MN, MR, MW, MX, NE, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SN, SZ, TD, TG, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW only).
RUPNIAK, Nadia, Melanie [GB/GB]; (GB) (For US Only)
Inventors: RUPNIAK, Nadia, Melanie; (GB)
Agent: HISCOCK, Ian; Merck & Co., Inc., European Patent Dept., Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB)
Priority Data:
9716457.8 04.08.1997 GB
PCT/EP97/06689 25.11.1997 EP
9812615.4 11.06.1998 GB
Title (EN) USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING AGGRESSIVE BEHAVIOUR DISORDERS
(FR) UTILISATION D'ANTAGONISTES DU RECEPTEUR NK-1 POUR LE TRAITEMENT DE TROUBLES DU COMPORTEMENT AGRESSIFS
Abstract: front page image
(EN)The present invention provides the use of an NK-1 receptor antagonist, and optionally an antipsychotic agent, for the manufacture of a medicament for the treatment or prevention of aggressive behaviour, methods of treatment using such an NK-1 receptor antagonist and pharmaceutical compositions and products comprising it.
(FR)La présente invention concerne l'utilisation d'un antagoniste du récepteur NK-1, pénétrant dans le SNC, à action prolongée, oralement actif, et éventuellement d'un agent antipsychotique, pour produire un médicament destiné au traitement ou à la prévention d'un comportement agressif, des méthodes de traitement utilisant cet antagoniste du récepteur NK-1, ainsi que des compositions et des produits pharmaceutiques le renfermant.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)